Clinical Trials Logo

Filter by:
NCT ID: NCT05296278 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Start date: December 25, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to explore the efficacy and biomarker explanation of IBI-323 combined with bevacizumab plus platinum based chemotherapy on ALK-rearranged non-small cell lung cancer who failed from first line Alectinib.

NCT ID: NCT05295355 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Effect of Tiotropium Bromide Combined With Odaterol on Small Airway Remodeling in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease

Start date: January 25, 2021
Phase: N/A
Study type: Interventional

72 patients with mild to moderate chronic obstructive pulmonary disease were planned to be enrolled in this study and then treated with olodaterol combined with thiotropium bromide, and thiotropium bromide, respectively, for 52 weeks. To assess the effect of the test drug on small airway remodeling in patients.

NCT ID: NCT05295212 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.

NCT ID: NCT05294978 Recruiting - Retinal Dystrophies Clinical Trials

EyeConic: Qualification for Cone-Optogenetics

Start date: July 1, 2021
Phase:
Study type: Observational

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

NCT ID: NCT05294822 Recruiting - Diabetes Clinical Trials

Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

This is a single-center, phase IIT clinical trial to evaluate autologous regenerative islet transplantation for insulin-dependent diabetes mellitus. Twenty patients with insulin-dependent diabetes mellitus will be enrolled: poor blood glucose control despite intensive exogenous insulin therapy. The primary endpoint will be defined by the return to normal blood glucose control without insulin at 12 months after transplantation.

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

NCT ID: NCT05294055 Recruiting - Multiple Myeloma Clinical Trials

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Start date: April 26, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.

NCT ID: NCT05293964 Recruiting - Breast Cancer Clinical Trials

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Start date: May 18, 2022
Phase: Phase 1
Study type: Interventional

This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

NCT ID: NCT05293405 Recruiting - Clinical trials for Autoimmune Encephalomyelitis

Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

Start date: December 14, 2021
Phase: N/A
Study type: Interventional

Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal surface proteins, synaptic receptors and intracellular antigens. MRI, as a current first-line imaging tool of CNS inflammation, is difficult to diagnose them because the majority of patients have normal MRI images, and only a few may show local signal or structural abnormalities (including inflammation, edema, or atrophy). The 18 kDa translocator protein (TSPO) expression in the CNS is upregulated in response to microglia activation. DPA-714 is high affinity for binding to TSPO, making 18F-labeled DPA-714 (18F-DPA-714) PET a very promising diagnostic imaging tool for neuroinflammation in patients with autoimmune encephalomyelitis.This study aims to explore the value of 18F-DPA-714 PET in the early diagnosis, therapeutic assessment and prognosis in patients with autoimmune encephalomyelitis.

NCT ID: NCT05293314 Recruiting - Bronchiectasis Clinical Trials

Assessment of an Exhaled Breath Test to Detect Bronchiectasis

Start date: July 1, 2022
Phase:
Study type: Observational

To investigate whether the breath test is able to detect bronchiectasis using breathomics. This study was conducted with a prospective specimen collection, evaluator-blinded, case-controlled clinical study designed to evaluate the accuracy of breathomics to diagnosis of bronchiectasis in adults.